← Ranking

PANW · Palo Alto Networks Inc

Changes to watch · 6 concrete new risks (regulation, debt and liquidity, technology and products)

10-K 2026-09-10 ↗ compared with the previous 10-K 10-K 2025-08-29 ↗

Closing price50-day average200-day average

Technical events and factor profile →

Summary

Palo Alto Networks adds risks from regulatory requirements in foreign jurisdictions and AI system vulnerabilities. Among the new risks: regulatory compliance expands in China and other countries, cloud provider capacity limitations impede customer onboarding and usage and customer configuration errors lead to security incidents and data breaches.

Automatic summary generated from the filing; it may contain inaccuracies.
Concrete new risks
6
Generic new risks
12
Filing
10-K · 2026-09-10

How the stock reacted

After the 10-K1 session5 sessions20 sessions
PANW+1.0%+12.1%+21.0%
Nasdaq-100 (QQQ)-1.1%-1.6%+5.9%
Difference+2.1%+13.7%+15.1%

From the close before the filing. Historical data, not a prediction.

What the concrete new risks are about

Regulation · 3Debt and liquidity · 2Technology and products · 1

New risks 18

Concrete fact Regulation
Regulatory compliance expands in China and other countries

Our products and subscriptions are subject to regulatory requirements in a number of foreign jurisdictions, and the scope and complexity of these requirements continue to expand. For example, in China, our products may be required to comply with cybersecurity and data security laws, including the Cybersecurity Law, the Data Security Law, and related regulations, and may be subject to network security review, critical information infrastructure protection requirements, and mandatory product certifications. Other jurisdictions impose similar requirements, including local testing and certification requirements, in-country data storage or processing mandates, source code review or escrow obligations, and restrictions on the use of foreign-developed encryption or security technologies. Compliance with these requirements is costly and time-consuming, and the regulatory landscape in many jurisdictions is evolving and subject to change with limited or no notice. If we are unable to obtain or maintain required certifications, approvals, or authorizations in a timely manner, or if new or revised requirements render our products or subscriptions non-compliant, we may be unable to sell, deploy, or support our products in affected markets, which could result in lost revenue opportunities, reputational harm, and a material adverse effect on our business, financial condition, and operating results.

17 more new risks

With Pro you see every new risk in each filing, with concrete facts separated from generic wording, and the filing history.

Go Pro

Already Pro? Log in

Key figures quarterly · USD

Revenue (TTM)
$11.5B
YoY growth
+34.5%
Operating margin
5.0%
Cash / debt
$2.5B / $2.0B
Jul 26Apr 26Jan 26Oct 25Jul 25
Revenue$3.4B$3.0B$2.6B$2.5B$2.5B
YoY growth+34.5%+31.1%+14.9%+15.7%+15.9%
Gross margin67.6%67.6%73.6%74.2%73.2%
Operating margin5.0%-6.1%15.3%12.5%19.6%
Net income-$282M-$177M$432M$334M$254M
Diluted EPS-0.46-0.220.610.470.36

XBRL data filed with the SEC. The fourth fiscal quarter is calculated as the full year minus the previous three quarters.

Factor profile percentile vs. the S&P 500 and the Nasdaq-100

Momentum
12 months excl. last: +81.5% · 6 months +103.8%
94
Trend quality
R² 0.79 · rising
94
Relative strength
+93.6% vs. the S&P 500 over 6 months
99
Volatility
60% annualised
91
Beta
beta 1.20
77
Distance from high
-18.6% from the 52-week high
38
Extension
-2.6 standard deviations from its 20-day average
2

0 = the lowest in the universe, 100 = the highest. It describes how the stock has behaved, not whether to buy or sell it. Screen stocks by factors

Management tone MD&A

+12

Similar than in the previous 10-K (2025-08-29: +11, +2 points)

10-K of 2026-09-10 · 20.9% positive sentences, 9.8% negative · 287 sentences analysed

Index from −100 to +100 calculated with FinBERT on the results discussion (MD&A). The change matters more than the level: some sectors always sound more cautious.

Top funds 13F

Duquesne Family Office · Stanley Druckenmiller
held since Q2 2026
0.9% $39.8M new
Bridgewater Associates · Ray Dalio — sold
ARK Investment Management · Cathie Wood — sold

Weight in each fund's portfolio and change vs. the previous quarter, from its latest 13F.

Recent material events (8-K)

2026-09-01 Results released 5 sessions: -8.7% vs Nasdaq-100 SEC ↗
2026-08-21 Executive or board changesBylaws or fiscal year change 5 sessions: +3.4% vs Nasdaq-100 SEC ↗
2026-06-02 Results released 5 sessions: -7.2% vs Nasdaq-100 SEC ↗

All material events for PANW →

Insiders · last 90 days

Buys
—
Discretionary sells
$9.2M
10b5-1 plan sells
$10.9M
2026-10-09 Bawa Aparna · Director Sell $70K SEC ↗
2026-10-09 Bawa Aparna · Director Sell $33K SEC ↗
2026-10-01 Paul Josh D. · Officer Sell (10b5-1 plan) $158K SEC ↗
2026-09-24 Golechha Dipak · CFO Sell (10b5-1 plan) $3.7M SEC ↗
2026-09-24 Golechha Dipak · CFO Sell (10b5-1 plan) $2.5M SEC ↗
2026-09-24 Golechha Dipak · CFO Sell (10b5-1 plan) $2.1M SEC ↗
2026-09-24 Golechha Dipak · CFO Sell (10b5-1 plan) $866K SEC ↗
2026-09-24 Golechha Dipak · CFO Sell (10b5-1 plan) $842K SEC ↗
2026-09-24 Golechha Dipak · CFO Sell (10b5-1 plan) $355K SEC ↗
2026-09-24 Golechha Dipak · CFO Sell (10b5-1 plan) $350K SEC ↗
2026-09-24 Bawa Aparna · Director Sell $102K SEC ↗
2026-09-24 Golechha Dipak · CFO Sell (10b5-1 plan) $40K SEC ↗
2026-09-17 GOETZ JAMES J · Director Sell $1.8M SEC ↗
2026-09-17 GOETZ JAMES J · Director Sell $1.6M SEC ↗
2026-09-17 GOETZ JAMES J · Director Sell $1.3M SEC ↗
2026-09-17 GOETZ JAMES J · Director Sell $570K SEC ↗
2026-09-17 GOETZ JAMES J · Director Sell $488K SEC ↗
2026-09-17 GOETZ JAMES J · Director Sell $381K SEC ↗
2026-09-17 GOETZ JAMES J · Director Sell $340K SEC ↗
2026-09-17 GOETZ JAMES J · Director Sell $335K SEC ↗

Source: SEC EDGAR. Automatic comparison of the risk factors section; it may contain extraction errors. Always check the original document. For information purposes only; not investment advice.